Here's yet another example of why big pharma can't do biotech - they keep sacking the scientists needed to develop drugs. I've lost count of the amount of times we see this.
http://www.fiercebiotech.com/story/merck-shutter-cubist-site-may-axing-128-staffers/2015-03-06
No surprise if we see Merck in a couple of years offloading remaining Cubist IP & programs they couldn't take further, for a biotech to buy cheaply, take it up to PIII then sell value added back to Merck.
Merck's CEO is a lawyer, not an ex soft drink Co. boss. Either way, still not much use to say a brilliant young upcoming biotech scientist looking for some mentorship as he/she goes about developing breakthrough medical drugs.
Arrowhead buys Novartis' RNAi assets, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)